Randox Laboratories and French diagnostics company Aterovax have announced a strategic partnership to commercialise Aterovax’s biomarker secreted phospholipase A2 (sPLA2) for the assessment of cardiovascular risk.
This marker independently predicts adverse outcomes in patients with stable coronary artery disease and is useful in the risk stratification of patients with acute coronary syndrome. Randox has exclusive rights to develop, manufacture and market the new test for use on automated immunoassay analysers and will develop the sPLA2 test for its own range of analysers and also other diagnostic analysers.
Dr Peter FitzGerald, Randox managing director, commented: “This was an exciting opportunity for Randox to expand its portfolio of cardiovascular disease (CVD) biomarkers and demonstrates continued investment in this field. The new SPLA2 test has been shown to add significant clinical value when combined with other biomarkers in the Randox range of tests, and offers us the opportunity to provide an effective panel of tests for CVD risk assessment with strong clinical utility.”
www.randox.com